Eagle Asset Management Inc. Makes New $3.95 Million Investment in TG Therapeutics, Inc. (NASDAQ:TGTX)

Eagle Asset Management Inc. purchased a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 168,795 shares of the biopharmaceutical company's stock, valued at approximately $3,948,000. Eagle Asset Management Inc. owned approximately 0.11% of TG Therapeutics at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in the company. NBC Securities Inc. grew its holdings in TG Therapeutics by 58.9% during the third quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company's stock worth $30,000 after purchasing an additional 485 shares during the period. Quarry LP boosted its stake in shares of TG Therapeutics by 9.1% during the 2nd quarter. Quarry LP now owns 6,003 shares of the biopharmaceutical company's stock worth $107,000 after acquiring an additional 503 shares during the period. Private Advisor Group LLC increased its holdings in shares of TG Therapeutics by 3.9% during the 3rd quarter. Private Advisor Group LLC now owns 14,407 shares of the biopharmaceutical company's stock worth $337,000 after acquiring an additional 542 shares during the last quarter. Blue Trust Inc. raised its stake in TG Therapeutics by 127.3% in the 3rd quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company's stock valued at $35,000 after acquiring an additional 849 shares during the period. Finally, KBC Group NV lifted its holdings in TG Therapeutics by 30.5% during the 3rd quarter. KBC Group NV now owns 4,675 shares of the biopharmaceutical company's stock valued at $109,000 after purchasing an additional 1,092 shares during the last quarter. Institutional investors and hedge funds own 58.58% of the company's stock.

Insider Buying and Selling

In other TG Therapeutics news, Director Sagar Lonial sold 5,000 shares of the firm's stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $30.44, for a total value of $152,200.00. Following the sale, the director now owns 100,195 shares in the company, valued at $3,049,935.80. This trade represents a 4.75 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 10.50% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several brokerages recently commented on TGTX. The Goldman Sachs Group lifted their target price on shares of TG Therapeutics from $20.00 to $22.00 and gave the stock a "neutral" rating in a report on Tuesday, November 5th. HC Wainwright upped their target price on TG Therapeutics from $49.00 to $55.00 and gave the company a "buy" rating in a research report on Tuesday, November 5th. B. Riley lifted their price target on TG Therapeutics from $29.00 to $34.00 and gave the stock a "buy" rating in a report on Wednesday, August 7th. JPMorgan Chase & Co. upped their price objective on TG Therapeutics from $30.00 to $43.00 and gave the company an "overweight" rating in a report on Monday. Finally, TD Cowen assumed coverage on TG Therapeutics in a report on Tuesday, October 29th. They set a "buy" rating and a $50.00 target price for the company. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $40.67.

TG Therapeutics Price Performance

TG Therapeutics stock traded down $0.46 during trading hours on Monday, reaching $34.61. 2,866,036 shares of the stock were exchanged, compared to its average volume of 3,698,648. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. TG Therapeutics, Inc. has a twelve month low of $12.30 and a twelve month high of $36.84. The company has a market cap of $5.39 billion, a P/E ratio of -357.76 and a beta of 2.19. The stock has a 50 day moving average of $25.62 and a two-hundred day moving average of $21.70.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its quarterly earnings data on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.03 by ($0.01). The firm had revenue of $83.90 million during the quarter, compared to the consensus estimate of $81.68 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The business's revenue was down 49.4% compared to the same quarter last year. During the same period last year, the business earned $0.73 earnings per share. Equities analysts expect that TG Therapeutics, Inc. will post 0.17 EPS for the current fiscal year.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.